Informatie:
Fout:
ID
45792
Beschrijving
Principal Investigator: Jorg J. Goronzy, MD PhD, Stanford University, Stanford, CA, USA MeSH: Herpes Zoster,Receptors, Antigen, T-Cell, alpha-beta,Vaccination https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001082 Diversity and size of the antigen-specific T cell receptor (TCR) repertoire are two critical determinants for successful control of chronic infection. Varicella zoster virus (VZV) that establishes latency during childhood is able to escape control mechanisms, in particular with increasing age. We examined the TCR diversity of VZV-specific CD4 T cells in individuals older than 50 years by studying three identical twin pairs and three unrelated individuals before and after vaccination with live attenuated VZV. While all individuals had a small number of dominant T cell clones, the breadth of the VZV-specific repertoire differed markedly among different individuals. A genetic influence was seen for the sharing of individual TCR sequences from antigen-specific cells, but not for repertoire richness or the selection of clonal dominance. VZV vaccination favored the expansion of infrequent VZV-specific TCRs including those from naïve T cells while leaving dominant T cell clones mostly unaffected.
Link
Trefwoorden
Versies (1)
- 22-06-23 22-06-23 - Chiara Middel
Houder van rechten
Jorg J. Goronzy, MD PhD, Stanford University, Stanford, CA, USA
Geüploaded op
22 juni 2023
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs001082 T Cell Responses to Varicella Zoster Virus
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This pedigree data table contains family relationships in the format of family IDs, subject IDs, father IDs, mother IDs, sex of subjects, and twin IDs.
- This subject phenotype table includes sex and age of subjects, occurance of herpes zoster, and detection of HSV1, HSV2, and CMV.
- This sample attributes table includes tissue type, analyte type, histological type, and day sample was collected.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This pedigree data table contains family relationships in the format of family IDs, subject IDs, father IDs, mother IDs, sex of subjects, and twin IDs.
- This subject phenotype table includes sex and age of subjects, occurance of herpes zoster, and detection of HSV1, HSV2, and CMV.
- This sample attributes table includes tissue type, analyte type, histological type, and day sample was collected.
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,2])
Elig.phs001082.v1.p1.1
Item
*Inclusion:*
boolean
C1512693 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.2
Item
Healthy individuals older than 50 years
boolean
C1708335 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,2])
Elig.phs001082.v1.p1.3
Item
*Exclusion:*
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.4
Item
History of shingles within 5 years of enrollment
boolean
C0262926 (UMLS CUI [1,1])
C0019360 (UMLS CUI [1,2])
C0332285 (UMLS CUI [1,3])
C0205451 (UMLS CUI [1,4])
C0439234 (UMLS CUI [1,5])
C1516879 (UMLS CUI [1,6])
C0019360 (UMLS CUI [1,2])
C0332285 (UMLS CUI [1,3])
C0205451 (UMLS CUI [1,4])
C0439234 (UMLS CUI [1,5])
C1516879 (UMLS CUI [1,6])
Elig.phs001082.v1.p1.5
Item
Prior vaccination with Zostavax vaccine for prevention of shingles
boolean
C2368628 (UMLS CUI [1,1])
C1720919 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C1720919 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.6
Item
History of severe allergic reactions to vaccine components, including gelatin and neomycin
boolean
C2106654 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0017237 (UMLS CUI [1,5])
C0027603 (UMLS CUI [1,6])
C0205082 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0017237 (UMLS CUI [1,5])
C0027603 (UMLS CUI [1,6])
Elig.phs001082.v1.p1.7
Item
Life-threatening reactions to previous vaccinations
boolean
C1517874 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0205156 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.8
Item
Adults weighing less than 110 pounds
boolean
C0005910 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.9
Item
Active systemic or serious concurrent illness, including febrile illness on the day of enrollment/vaccination
boolean
C0009488 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0442893 (UMLS CUI [1,3])
C0205404 (UMLS CUI [1,4])
C0221423 (UMLS CUI [1,5])
C0743842 (UMLS CUI [1,6])
C0040223 (UMLS CUI [1,7])
C0042196 (UMLS CUI [1,8])
C1516879 (UMLS CUI [1,9])
C0205177 (UMLS CUI [1,2])
C0442893 (UMLS CUI [1,3])
C0205404 (UMLS CUI [1,4])
C0221423 (UMLS CUI [1,5])
C0743842 (UMLS CUI [1,6])
C0040223 (UMLS CUI [1,7])
C0042196 (UMLS CUI [1,8])
C1516879 (UMLS CUI [1,9])
Elig.phs001082.v1.p1.10
Item
History of immunodeficiency disorder
boolean
C0262926 (UMLS CUI [1,1])
C0021051 (UMLS CUI [1,2])
C0021051 (UMLS CUI [1,2])
Elig.phs001082.v1.p1.11
Item
Chronic HIV, Hepatitis B or Hepatitis C infection
boolean
C0008679 (UMLS CUI [1,1])
C0019693 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,3])
C0019196 (UMLS CUI [1,4])
C0019693 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,3])
C0019196 (UMLS CUI [1,4])
Elig.phs001082.v1.p1.12
Item
Known or suspected impairment of immunologic function, including, but not limited to clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
boolean
C0205309 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0004364 (UMLS CUI [1,3])
C0221099 (UMLS CUI [1,4])
C1817756 (UMLS CUI [1,5])
C1512693 (UMLS CUI [1,6])
C2985739 (UMLS CUI [1,7])
C0023895 (UMLS CUI [1,8])
C0011854 (UMLS CUI [1,9])
C0205082 (UMLS CUI [1,10])
C0022658 (UMLS CUI [1,11])
C0205081 (UMLS CUI [1,12])
C0205394 (UMLS CUI [1,13])
C0008679 (UMLS CUI [1,14])
C1444641 (UMLS CUI [1,15])
C1113679 (UMLS CUI [1,16])
C0525058 (UMLS CUI [1,17])
C0750491 (UMLS CUI [1,2])
C0004364 (UMLS CUI [1,3])
C0221099 (UMLS CUI [1,4])
C1817756 (UMLS CUI [1,5])
C1512693 (UMLS CUI [1,6])
C2985739 (UMLS CUI [1,7])
C0023895 (UMLS CUI [1,8])
C0011854 (UMLS CUI [1,9])
C0205082 (UMLS CUI [1,10])
C0022658 (UMLS CUI [1,11])
C0205081 (UMLS CUI [1,12])
C0205394 (UMLS CUI [1,13])
C0008679 (UMLS CUI [1,14])
C1444641 (UMLS CUI [1,15])
C1113679 (UMLS CUI [1,16])
C0525058 (UMLS CUI [1,17])
Elig.phs001082.v1.p1.13
Item
Recent or current use of immunosuppressive medication, or anticipated use during study period, including systemic corticosteroids (corticosteroid nasal sprays, inhaled steroids and topical steroids are permissible).
boolean
C0332185 (UMLS CUI [1,1])
C2827774 (UMLS CUI [1,2])
C0021081 (UMLS CUI [1,3])
C3840775 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C0021081 (UMLS CUI [2,3])
C0347984 (UMLS CUI [2,4])
C0008976 (UMLS CUI [2,5])
C1512693 (UMLS CUI [2,6])
C2825233 (UMLS CUI [2,7])
C2827774 (UMLS CUI [1,2])
C0021081 (UMLS CUI [1,3])
C3840775 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C0021081 (UMLS CUI [2,3])
C0347984 (UMLS CUI [2,4])
C0008976 (UMLS CUI [2,5])
C1512693 (UMLS CUI [2,6])
C2825233 (UMLS CUI [2,7])
Elig.phs001082.v1.p1.14
Item
Blood pressure >150 systolic or >95 diastolic at Visit 1 12. History of chemotherapy treatment for cancer. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer with recurrence in the past year and any hematologic cancer such as leukemia or lymphoma), which in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol. Prostate cancer may be acceptable if no metastases and not undergoing treatment with immunosuppressive medications.
boolean
C0005823 (UMLS CUI [1,1])
C1320303 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0006826 (UMLS CUI [2,3])
C1707251 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C1705847 (UMLS CUI [3,3])
C0007117 (UMLS CUI [3,4])
C0553723 (UMLS CUI [3,5])
C1512693 (UMLS CUI [3,6])
C0280100 (UMLS CUI [3,7])
C0678222 (UMLS CUI [3,8])
C0034897 (UMLS CUI [3,9])
C4086728 (UMLS CUI [3,10])
C0376545 (UMLS CUI [3,11])
C0023418 (UMLS CUI [3,12])
C0024299 (UMLS CUI [3,13])
C1444641 (UMLS CUI [3,14])
C1113679 (UMLS CUI [3,15])
C0525058 (UMLS CUI [3,16])
C0600139 (UMLS CUI [4,1])
C3844350 (UMLS CUI [4,2])
C1879533 (UMLS CUI [4,3])
C0445092 (UMLS CUI [4,4])
C0332197 (UMLS CUI [4,5])
C0087111 (UMLS CUI [4,6])
C0021081 (UMLS CUI [4,7])
C1320303 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0006826 (UMLS CUI [2,3])
C1707251 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C1705847 (UMLS CUI [3,3])
C0007117 (UMLS CUI [3,4])
C0553723 (UMLS CUI [3,5])
C1512693 (UMLS CUI [3,6])
C0280100 (UMLS CUI [3,7])
C0678222 (UMLS CUI [3,8])
C0034897 (UMLS CUI [3,9])
C4086728 (UMLS CUI [3,10])
C0376545 (UMLS CUI [3,11])
C0023418 (UMLS CUI [3,12])
C0024299 (UMLS CUI [3,13])
C1444641 (UMLS CUI [3,14])
C1113679 (UMLS CUI [3,15])
C0525058 (UMLS CUI [3,16])
C0600139 (UMLS CUI [4,1])
C3844350 (UMLS CUI [4,2])
C1879533 (UMLS CUI [4,3])
C0445092 (UMLS CUI [4,4])
C0332197 (UMLS CUI [4,5])
C0087111 (UMLS CUI [4,6])
C0021081 (UMLS CUI [4,7])
Elig.phs001082.v1.p1.15
Item
Autoimmune disease, including rheumatoid arthritis, treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel, which in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol (thyroid disease may be acceptable).
boolean
C0004364 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0332293 (UMLS CUI [1,3])
C0021081 (UMLS CUI [1,4])
C0025677 (UMLS CUI [1,5])
C0032952 (UMLS CUI [1,6])
C0699177 (UMLS CUI [1,7])
C0720193 (UMLS CUI [1,8])
C1444641 (UMLS CUI [1,9])
C1113679 (UMLS CUI [1,10])
C0525058 (UMLS CUI [1,11])
C0040128 (UMLS CUI [2,1])
C3844350 (UMLS CUI [2,2])
C1879533 (UMLS CUI [2,3])
C0003873 (UMLS CUI [1,2])
C0332293 (UMLS CUI [1,3])
C0021081 (UMLS CUI [1,4])
C0025677 (UMLS CUI [1,5])
C0032952 (UMLS CUI [1,6])
C0699177 (UMLS CUI [1,7])
C0720193 (UMLS CUI [1,8])
C1444641 (UMLS CUI [1,9])
C1113679 (UMLS CUI [1,10])
C0525058 (UMLS CUI [1,11])
C0040128 (UMLS CUI [2,1])
C3844350 (UMLS CUI [2,2])
C1879533 (UMLS CUI [2,3])
Elig.phs001082.v1.p1.16
Item
History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
boolean
C0262926 (UMLS CUI [1,1])
C0018939 (UMLS CUI [1,2])
C0022658 (UMLS CUI [1,3])
C0019045 (UMLS CUI [1,4])
C1514873 (UMLS CUI [1,5])
C0205272 (UMLS CUI [1,6])
C1522577 (UMLS CUI [1,7])
C0019993 (UMLS CUI [1,8])
C0347984 (UMLS CUI [1,9])
C4086728 (UMLS CUI [1,10])
C0018939 (UMLS CUI [1,2])
C0022658 (UMLS CUI [1,3])
C0019045 (UMLS CUI [1,4])
C1514873 (UMLS CUI [1,5])
C0205272 (UMLS CUI [1,6])
C1522577 (UMLS CUI [1,7])
C0019993 (UMLS CUI [1,8])
C0347984 (UMLS CUI [1,9])
C4086728 (UMLS CUI [1,10])
Elig.phs001082.v1.p1.17
Item
Use of anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except aspirin up to 325 mg. daily), Plavix or Aggrenox which may, in the opinion of the investigator, jeopardize volunteer safety or compliance with the protocol.
boolean
C1524063 (UMLS CUI [1,1])
C0003280 (UMLS CUI [1,2])
C0699129 (UMLS CUI [1,3])
C0728963 (UMLS CUI [1,4])
C0085826 (UMLS CUI [1,5])
C0004057 (UMLS CUI [1,6])
C2348070 (UMLS CUI [1,7])
C0633084 (UMLS CUI [1,8])
C0732282 (UMLS CUI [1,9])
C2945640 (UMLS CUI [1,10])
C1113679 (UMLS CUI [1,11])
C0525058 (UMLS CUI [1,12])
C0003280 (UMLS CUI [1,2])
C0699129 (UMLS CUI [1,3])
C0728963 (UMLS CUI [1,4])
C0085826 (UMLS CUI [1,5])
C0004057 (UMLS CUI [1,6])
C2348070 (UMLS CUI [1,7])
C0633084 (UMLS CUI [1,8])
C0732282 (UMLS CUI [1,9])
C2945640 (UMLS CUI [1,10])
C1113679 (UMLS CUI [1,11])
C0525058 (UMLS CUI [1,12])
Elig.phs001082.v1.p1.18
Item
Receipt of blood or blood products within 6 months prior to enrollment and during the study period
boolean
C0371802 (UMLS CUI [1,1])
C0205452 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
C0205452 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.19
Item
Use of antiviral medications within 24 hrs. prior to enrollment, and for the 14 days following study vaccination.
boolean
C1524063 (UMLS CUI [1,1])
C0280274 (UMLS CUI [1,2])
C0439228 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0205448 (UMLS CUI [1,6])
C0439230 (UMLS CUI [1,7])
C0332282 (UMLS CUI [1,8])
C0042196 (UMLS CUI [1,9])
C0280274 (UMLS CUI [1,2])
C0439228 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0205448 (UMLS CUI [1,6])
C0439230 (UMLS CUI [1,7])
C0332282 (UMLS CUI [1,8])
C0042196 (UMLS CUI [1,9])
Elig.phs001082.v1.p1.20
Item
Inactivated vaccine within 14 days prior to enrollment and during study period
boolean
C0042212 (UMLS CUI [1,1])
C0205448 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
C0205448 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.21
Item
Live, attenuated vaccine within 60 days prior to enrollment and during study period
boolean
C0042211 (UMLS CUI [1,1])
C0205448 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
C0205448 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.22
Item
Pregnant or lactating woman, planning to become pregnant (pregnancy should be avoided for 3 months following administration of Zostavax vaccine).
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C2081645 (UMLS CUI [1,3])
C0006147 (UMLS CUI [1,2])
C2081645 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.23
Item
Use of investigational agents within 30 days prior to enrollment and during study period
boolean
C1524063 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
C0013230 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.24
Item
Donation of a unit of blood within 6 weeks prior to enrollment and during study period
boolean
C0005794 (UMLS CUI [1,1])
C0205452 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
C0205452 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.25
Item
Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol
boolean
C0004936 (UMLS CUI [1,1])
C0014006 (UMLS CUI [1,2])
C0516937 (UMLS CUI [1,3])
C0332196 (UMLS CUI [1,4])
C0525058 (UMLS CUI [1,5])
C0014006 (UMLS CUI [1,2])
C0516937 (UMLS CUI [1,3])
C0332196 (UMLS CUI [1,4])
C0525058 (UMLS CUI [1,5])
Elig.phs001082.v1.p1.26
Item
Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
boolean
C0348080 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C1113679 (UMLS CUI [1,4])
C0683954 (UMLS CUI [1,5])
C1273101 (UMLS CUI [1,6])
C0085732 (UMLS CUI [1,7])
C0525058 (UMLS CUI [1,8])
C0012634 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C1113679 (UMLS CUI [1,4])
C0683954 (UMLS CUI [1,5])
C1273101 (UMLS CUI [1,6])
C0085732 (UMLS CUI [1,7])
C0525058 (UMLS CUI [1,8])
Geen commentaren